High-dose methotrexate therapy for a child with B-cell precursor acute
lymphoblastic leukemia and congenital solitary kidney
High-dose methotrexate (HD-MTX) is a key drug in the treatment of
various cancers. Massive fluid infusion is necessary during HD-MTX
therapy to ensure proper methotrexate excretion. There are no reports on
the safety of HD-MTX therapy in patients with congenital solitary kidney
(CSK). A 5-year-old male child with CSK and B-cell precursor acute
lymphoblastic leukemia was treated with four cycles of HD-MTX therapy.
HD-MTX therapy was safely administered without delayed MTX excretion or
renal dysfunction. This case showed that HD-MTX therapy was well
tolerated by a pediatric patient with CSK.